News & Updates
— WU-NK-101 exhibited enhanced metabolic flexibility and resistance to tumor microenvironment (TME) immunosuppression relative to conventional natural killer (NK) cells — — WU-NK-101 demonstrated robust anti-tumor activity in vitro and in vivo in preclinical models of acute myeloid leukemia (AML) — — Data support the development of WU-NK-101 for AML and solid tumor indications —…
Read More
Preclinical data demonstrate VIP152 as the most selective CDK9 inhibitor compared with other CDK9 inhibitors, with the most robust MYC mRNA downregulation Clinical data show improved selectivity, target modulation, early signs of clinical efficacy, and cardiac safety in lymphoma patients treated with VIP152 Excerpt from the Press Release: PALO ALTO, Calif., June 10, 2022 (GLOBE…
Read More
– Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment– – Updated data from Phase III CLL14 study of Venclexta (venetoclax) plus Gazyva (obinutuzumab) showed more than…
Read More
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., June 9, 2022 /PRNewswire/ — CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced preclinical data in a hamster model using CVXGA1, a COVID-19 vaccine candidate currently in Phase 1 clinical trials. The data show that CVXGA1,…
Read More
Excerpt from the Press Release: SAN DIEGO, June 2, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the acceptance of seven key oncology research abstracts authored in collaboration with Illumina at the American Society of Clinical Oncology (ASCO) annual meeting taking place June 3 – June 7…
Read More
Excerpt from the Press Release: SAN DIEGO & HOUSTON–(BUSINESS WIRE)–National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and…
Read More
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein…
Read More
-TQS-168 was well tolerated and demonstrated excellent pharmacokinetic properties- -Tranquis plans to start a Phase 2 trial in ALS by the end of 2022- Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases,…
Read MoreConfirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some…
Read More
STI-1558, an oral SARS-CoV-2 main protease inhibitor, is specifically designed as a standalone treatment and prevention of COVID-19 without the co-administration of ritonavir as a booster for CYP3A4 inhibition. STI-1558 is also a Cathepsin L inhibitor, which may block effective viral entry into host cells without accelerating viral mutations and could work in conjunction with…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?